Eloxx Pharmaceuticals, Inc.
ELOX · XNASCIK 1035354fmd_17GKSK9BYRX5424J4QT0PG81ZCManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 1998 to Jun 30, 2026, 72 periods
| Line item | FY2017 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 0 | 6 | 0 |
| Research and development | – | 16 | 20 | 26 | 15 | 23 | 24 | 9 | 4 | 3 |
| Total operating expenses | – | 20 | 48 | 51 | 33 | 66 | 34 | 17 | 9 | 6 |
| Operating income | – | (20) | (48) | (51) | (33) | (66) | (34) | (17) | (2) | (6) |
| Interest expense | – | 0 | – | – | – | – | – | – | – | – |
| Interest and investment income | – | – | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | (1) | 1 | (0) | (1) | (1) | (2) | 0 | (0) | 0 |
| Income before taxes | – | (21) | (47) | (51) | (35) | (67) | (36) | (17) | (3) | (6) |
| Income tax expense | (1) | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (20) | (47) | (51) | (35) | (67) | (36) | (17) | (3) | (6) |
| Net income | – | (21) | (47) | (51) | (35) | (67) | (36) | (17) | (3) | (6) |
| Net income to common shareholders | (6) | – | – | – | – | – | – | – | – | – |